New Wound Management of Driveline Infections with Cold Atmospheric Plasma
We’re ecstatic to see Dr Jamila Kremer’s publication, “New Wound Management of Driveline Infections with Cold Atmospheric Plasma” is now live for public viewing. The paper can be viewed here: https://doi.org/10.3390/jcdd9110405.
The use of our Adtec cold plasma medical device has greatly benefitted her LVAD infection patients treated at the University Heidelberg Hospital since 2019. The results stipulate a stronger infection management advantage over conventional therapy alone for LVAD infections. This is coupled with the benefit of our cold plasma being safe, painless, contact-free and free from side effects.
Driveline infections are the most prevalent infections and reported in up to 60% of LVAD patient cases. Infection of the LVAD system is the fourth most common cause of death within one year after implantation. Dr Kremer’s publication documents Adtec cold plasma treated patients showed a 100% survival rate.
For more information about the benefits of our Cold Plasma medical device, contact us at info@adtecplasma.com
The ISHLT discusses the Cold Plasma Project
We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.
Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.
We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.
https://youtu.be/6-L0sgXLx9o
Taiwan Wound Therapy Society Conference, March 2022
Sharing some photos from last weekend at the Taiwan Wound Therapy Society conference.
Our medical distributor, SG Biomedical, had a productive weekend demonstrating our SteriPlas to doctors and nurses keen to learn about the benefits of cold plasma for the treatment of wounds, surgical site infections and medical dermatology.
For more information about the Adtec SteriPlas and how to obtain this in the SE Asia region, please contact our distributor SG Biomedical for more information.
ToGCPiCPT
Congratulations to our Business Development Manager, Jeiram, for his published chapter in the “Textbook of Good Clinical Practice in Cold Plasma Therapy”. This prestigious book houses powerful material from esteemed authors in the cold plasma medicine field.
Jeiram’s chapter, “SteriPlas® and PlasmaTact®”, discusses the importance of Adtec Healthcare’s influence in the cold plasma medicine field from being the first company ever to conduct cold plasma clinical trials on wounds and to our modern day clinical efficacy in wounds, surgical site infections and medical dermatology skin conditions.
You can view this chapter here: https://doi.org/10.1007/978-3-030-87857-3_18
For more information about our cold plasma medical and non-medical devices, please contact us at info@adtecplasma.com
The Safety and Reliability of our Cold Plasma
Is our cold plasma safe?
Yes!
As you can see from the photo, our Adtec technician demonstrates touching the cold plasma jet.
An extensive list of practical tests and experiments were conducted during our first stage, pre clinical studies and ongoing post-market studies. This allowed us to carefully develop a cold plasma medical device that could bring all the antibacterial benefits but at the same time remain painless and contact-free so that it could be well tolerated in patient treatments. We were after all the first company worldwide to introduce cold plasma treatment on wounds demonstrated in our clinical trials.
As cold plasma can be generated through a variety of ways, they are also dependent on the plasma source design and surrounding environment. The components of plasma include reactive oxygen and nitrogen species and UV that need to be controlled to ensure they are within safe levels for medical use. Some plasma devices may also deliver fluctuating inconsistent cold plasma output as they are sensitive to changes in humidity and temperature in the treatment room. This may often result in undesirable side effects.
Because the Adtec SteriPlas is a low energy, microwave-powered, cold atmospheric argon plasma medical device this means its safety remains the main priority in line with delivering repeatable and successful results. It is also the reason why we are proud to state our medical device has NO side effects associated to it.
Our patented 6 electrode Cold Plasma Torch
The Adtec SteriPlas features a patented 6 electrode cold plasma torch. It’s proven efficacy for the destruction of all forms of bacteria including multi-resistant bugs makes it an alternative to antibiotic therapy for the treatment of wounds, surgical site infections and medical dermatology skin conditions. This is due to the unique physical mode of action delivered with our cold plasma as opposed to the chemical mode of action demonstrated with antibiotics. Broader studies have shown that antimicrobial resistance is unlikely to be generated with cold plasma treatment because of this.
A huge collection of our peer reviewed publications documents the clinical efficacy and safety of our medical device across a broad range of conditions including diabetic foot ulcers, left ventricular assist device (LVAD) infections, deep sternal wound infections, actinic keratoses and acne.
To learn more about our medical device or to obtain one in your clinic practice, please contact us at info@adtecplasma.com
The first cold plasma medical device to treat Scleroderma
We congratulate Dr Stephanie Ardnt and Prof. Sigrid Karrer from the University Hospital Regensburg for their recent publication, “The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo”.
This publication features the use of our Adtec SteriPlas and shows strong efficacy for the treatment of Scleroderma, which up to now has not yet been evaluated by CAP. The extensive study documents significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. This study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.
https://doi.org/10.3390/biomedicines9111545
Deep Sternal Wound Infections (DWSI) and the Adtec SteriPlas
Unlike other cold plasma medical devices currently present on the market, the Adtec SteriPlas is not limited to the treatment of superficial wounds only.
For example, deep sternal wound infections (DSWIs) are a potentially devastating complication of median sternotomy performed in cardiac surgery. These large wound cavities are prone to infections and there is a concerningly high morbidity and mortality rate associated to these patients. The use of conventional therapies alone has shown to not always be successful and expensive muscle flap surgery is usually required.
The large 12cm2 treatment area of the Adtec SteriPlas covers a greater surface area of the wound compared to its competitors. This allows the benefit of a quick 2 minute treatment time for every 12cm2 covered. Because of its propulsion towards the treatment site, the cold plasma components work quickly to defeat bacteria and allow the management of the infection. The use of the Adtec SteriPlas has shown to accelerate healing rates and prevent the need for expensive surgery options that would otherwise have been needed.
It has been praised as a lifesaving medical device and is now widely used across multiple hospitals for the management of DWSIs.
Promising, consistent and reliable results achieved with the Adtec SteriPlas
Whilst Left ventricular assist devices (LVADs) have become essential mechanical pumps for patients who have had end stage heart failures, they are also prone to infections especially with the presence of biofilm that complicates treatment options. Cardiologists often rely on conventional antibiotic therapy but with rising antimicrobial resistance rates, they sometimes offer little to no help in achieving stabilisation.
The strong properties of the Adtec SteriPlas cold plasma has been proven to offer complete stabilisation of the LVAD system by destroying all forms of multi-resistant bacteria present, even if they are protected within biofilm. This is due to the unique cold plasma properties that can travel through the gaps around and down the driveline to reach the site of biofilm. This area would normally have been difficult to treat with conventional therapies such as antimicrobial dressings as they are hard to reach, but the Adtec SteriPlas has shown to travel to these sites with ease due to its remarkable antibacterial gaseous properties.
To learn more about our strong collection of clinical evidence, please contact us at info@adtecplasma.com to learn more
The SteriPlas sets foot in the U.S.A.
We are excited to share news of our collaboration with The Southern Illinois University in United States of America. Our Adtec SteriPlas will be used as part of their study to examine the effect of cold plasma on a variety of infection burn model cases in a research laboratory setting. This study aims to help tackle the outbreaks of antimicrobial resistant microorganisms that continues to be an issue for burns cases. We look forward to providing more information and the results as the study progresses.